rivoceranib
hlb bio group
['great work', 'rivoceranib']
today, accoi met dr. kang at #asco2022 great work on a phase 2 study of the oral vascular endothelial growth factor receptor 2 (vegfr2) inhibitor rivoceranib for recurrent or metastatic #adenoidcysticcarcinoma read here #rarecancer 
Adenoid Cystic Carcinoma Organization International.  Creating a worldwide community of ACC patients & their loved ones sharing information, support and hope.